Astepro patent granted

 | Quelle: Meda AB Meda AB 

Astepro patent granted

 

The United States Patent and Trademark Office (USPTO) today issued a patent
related to Astepro (azelastine) nasal spray. This patent will be listed in the
FDA's Approved Drug Products List (the Orange Book). The Astepro patent is valid
until 2028.

"I’m delighted that the US patent for Astepro has been granted. This is great
news for our azelastine franchise", said Anders Lönner, CEO of Meda AB.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878

Anhänge